Regeneron has yet again added to their arsenal of extremely influential U.S. Food and Drug Administration (FDA) approvals with their Inmazeb antibody, a treatment for children, adults, and newborns with mothers who have tested positive for Ebola, a deadly virus that most frequently affects those in the African sub-Sahara. The antibody mixture was engineered to prevent the virus from entering the host’s body as well as utilizing other immune cells to fight the infection. In July, Regeneron worked with global health organizations such as the World Health Organization (WHO) to plan the distribution of the new drug.

Read more here.

More on: